ZIM Laboratories has notified the stock exchanges of an upcoming Board of Directors meeting, scheduled for Tuesday, May 19, 2026. The intimation was issued on May 12, 2026, under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting has been convened to, among other matters, consider and approve the Audited Financial Results of the company for the quarter and year ended March 31, 2026. The results will be reviewed on both a Standalone and Consolidated basis.

The key details of the scheduled board meeting are outlined below:

Trading Window Closure

In connection with the board meeting, ZIM Laboratories has also communicated the closure of its trading window in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's own Code of Conduct to Regulate, Monitor and Report Trading by Insiders.

The trading window closure details are as follows:

The trading window restriction prohibits designated persons from dealing in the securities of ZIM Laboratories during the specified period. The window is set to reopen after May 21, 2026, following the conclusion of the board meeting and dissemination of financial results.

The intimation was signed by Piyush Nikhade, Company Secretary and Compliance Officer (Membership No. A38972), on behalf of ZIM Laboratories Limited.

ZIM Laboratories Limited has notified the stock exchanges of the completion of a European Good Manufacturing Practices (EU GMP) inspection at its manufacturing facility. The inspection, carried out by German and Portuguese regulatory authorities, was conducted from May 4, 2026 to May 7, 2026, marking a significant step in the company's EU GMP compliance process. This update follows the company's earlier intimation dated August 1, 2025, regarding the EU GMP Inspection Outcome.

Inspection Details

The audit was held at ZIM Laboratories' manufacturing facility situated at B-21/22, MIDC Area, Kalmeshwar – 441 501, District Nagpur, Maharashtra. The inspection was undertaken as part of the European Good Manufacturing Practices compliance process, with the German and Portuguese regulatory authorities jointly overseeing the audit.

Key details of the inspection are outlined below:

Regulatory Compliance Commitment

ZIM Laboratories has stated that it remains committed to the highest standards of quality and regulatory compliance across all its operations. The company has also indicated that it will continue to update stakeholders on the progress of this matter as appropriate.

The disclosure was made under Regulation 30 and was filed with both BSE Limited and the National Stock Exchange of India Limited. The intimation was signed by Piyush Nikhade, Company Secretary and Compliance Officer (Membership No. A38972), on May 8, 2026.